Terence Flynn
Stock Analyst at Morgan Stanley
(3.97)
# 605
Out of 5,026 analysts
210
Total ratings
59.43%
Success rate
8.38%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $178 → $190 | $192.01 | -1.05% | 25 | Oct 15, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $16 → $15 | $10.67 | +40.58% | 6 | Oct 14, 2025 | |
| PFE Pfizer | Maintains: Equal-Weight | $33 → $32 | $24.52 | +30.51% | 19 | Oct 10, 2025 | |
| RPRX Royalty Pharma | Maintains: Overweight | $55 → $54 | $36.26 | +48.92% | 13 | Oct 10, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $133 → $131 | $106.50 | +23.00% | 5 | Oct 10, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $439 → $438 | $412.74 | +6.12% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $328 → $435 | $431.91 | +0.72% | 11 | Oct 10, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,028 → $1,023 | $832.62 | +22.87% | 21 | Oct 3, 2025 | |
| ALMS Alumis | Maintains: Overweight | $23 → $22 | $4.83 | +355.49% | 2 | Aug 15, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $63 → $54 | $17.38 | +210.70% | 3 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $330 → $333 | $301.59 | +10.41% | 9 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $255 | $226.61 | +12.53% | 18 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $99 → $98 | $85.29 | +14.90% | 17 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $34 | $43.53 | -21.89% | 11 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $9.90 | +11.11% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $22 | $17.10 | +28.65% | 6 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $10 | $9.42 | +6.21% | 10 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $70.76 | -54.78% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $26.38 | -58.30% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $28.78 | +310.01% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.45 | +227.20% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $146.89 | +196.82% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $482.38 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.17 | - | 1 | Jul 21, 2017 |
Johnson & Johnson
Oct 15, 2025
Maintains: Equal-Weight
Price Target: $178 → $190
Current: $192.01
Upside: -1.05%
Nurix Therapeutics
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $10.67
Upside: +40.58%
Pfizer
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $33 → $32
Current: $24.52
Upside: +30.51%
Royalty Pharma
Oct 10, 2025
Maintains: Overweight
Price Target: $55 → $54
Current: $36.26
Upside: +48.92%
BioNTech SE
Oct 10, 2025
Maintains: Overweight
Price Target: $133 → $131
Current: $106.50
Upside: +23.00%
Vertex Pharmaceuticals
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $439 → $438
Current: $412.74
Upside: +6.12%
United Therapeutics
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $328 → $435
Current: $431.91
Upside: +0.72%
Eli Lilly and Company
Oct 3, 2025
Maintains: Overweight
Price Target: $1,028 → $1,023
Current: $832.62
Upside: +22.87%
Alumis
Aug 15, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $4.83
Upside: +355.49%
Biohaven
Aug 12, 2025
Maintains: Overweight
Price Target: $63 → $54
Current: $17.38
Upside: +210.70%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $330 → $333
Current: $301.59
Upside: +10.41%
Aug 1, 2025
Maintains: Overweight
Price Target: $250 → $255
Current: $226.61
Upside: +12.53%
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $99 → $98
Current: $85.29
Upside: +14.90%
Jul 10, 2025
Maintains: Underweight
Price Target: $36 → $34
Current: $43.53
Upside: -21.89%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $9.90
Upside: +11.11%
May 9, 2025
Maintains: Overweight
Price Target: $24 → $22
Current: $17.10
Upside: +28.65%
May 5, 2025
Maintains: Equal-Weight
Price Target: $15 → $10
Current: $9.42
Upside: +6.21%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $70.76
Upside: -54.78%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $26.38
Upside: -58.30%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $28.78
Upside: +310.01%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.45
Upside: +227.20%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $146.89
Upside: +196.82%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $482.38
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $11.17
Upside: -